Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fosmanogepix Formulations
NCT05491733Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fosmanogepix in invasive fungal infection (IFI) (3 arms), sponsored by Basilea Pharmaceutica. Primary endpoints: Maximum Observed Plasma Concentration at 312 hours, Time to Reach Maximum Observed Plasma Concentration at 312 hours and 13 more. Started Mar 2021; status: completed.
02
Drugs
fosmanogepix
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT05491733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491733.